Enclomiphene vs TRT: Which One Preserves Fertility

Most men researching enclomiphene vs TRT arrive at the question from one of two directions. Either they want their testosterone fixed and have just learned that TRT will shut down their fertility, or they are already on TRT, want children sooner than they expected, and are looking for a way out.

Both are good reasons to understand the difference, because these two treatments are frequently described as alternatives when they are closer to opposites. They arrive at the same lab value by inverting the same feedback loop.

Why the Axis Matters Before Anything Else

Testosterone production runs on a loop. The hypothalamus releases GnRH, which prompts the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH tells the Leydig cells in the testes to make testosterone; FSH, alongside intratesticular testosterone, supports sperm production. Rising testosterone and estradiol then signal back to the hypothalamus and pituitary to slow down.

That last step — negative feedback — is the entire mechanism at issue.

When testosterone arrives from outside the body, the brain reads it as sufficient and reduces GnRH, LH, and FSH. Testosterone in the blood goes up while the signal to the testes goes down. Sperm production falls, sometimes to zero, and the testes may shrink. This is expected pharmacology rather than a side effect of a badly run protocol.

Enclomiphene does the reverse. It interferes with the feedback signal itself, so the brain acts as though testosterone were low and increases LH and FSH output. Testosterone rises because your own testes are being told, more insistently, to produce it.

Enclomiphene vs TRT: The Mechanism Difference

The row that decides most cases is the third one. The row that disqualifies enclomiphene for a meaningful minority of men is the fifth.

What Enclomiphene Actually Is

Enclomiphene citrate is a selective estrogen receptor modulator — a SERM. It occupies estrogen receptors in the hypothalamus and pituitary without activating them, which blocks the feedback signal and releases the brake on LH and FSH.

It is worth being precise about how it relates to Clomid, because the two get used interchangeably and should not be.

Clomiphene citrate is a mixture of two stereoisomers: enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). Enclomiphene produces the desired effect on gonadotropins and testosterone. Zuclomiphene has substantially more estrogenic activity and a much longer half-life, so it accumulates over weeks of continued dosing (1). That accumulation is generally held responsible for several of the complaints men report on long-term Clomid — mood changes, visual disturbance, and a sense that the benefit fades.

Enclomiphene is the isolated isomer. The clinical argument for it over Clomid is not that it does something different, but that it does the same thing without carrying the isomer you did not want.

What the Trials Show

Enclomiphene has a real clinical trial record, which is unusual for something in this corner of the market. It is worth knowing what those trials did and did not establish.

Pharmacodynamics. A study in men with secondary hypogonadism established that enclomiphene raises LH, FSH, and total testosterone in a dose-dependent manner, and characterized its pharmacokinetics (2).

The head-to-head against testosterone gel. This is the study that matters most for the fertility question. In a randomized comparison, enclomiphene and topical testosterone both raised total testosterone into the normal range — but only enclomiphene maintained sperm counts, while the gel group showed the suppression that exogenous testosterone predicts (3). A phase II trial reported the same pattern, describing enclomiphene as stimulating testosterone production while preventing oligospermia (4).

Phase III. Two parallel randomized, double-blind, placebo-controlled multicentre phase III studies evaluated two doses of enclomiphene against testosterone gel in overweight men aged 18 to 60 with secondary hypogonadism (5).

What the trials did not produce. Approval. Enclomiphene was developed as Androxal and was not approved by the FDA, which is why there is no branded product and why every prescription today is compounded. The reasons were regulatory and endpoint-related rather than a safety finding, but the outcome is the same: no label, no standardized product, and quality that depends on the compounding pharmacy.

That is the honest summary. Better trial evidence than most things prescribed alongside it, and no approval at the end of it.

The Fertility Question, Specifically

This is where the choice is least ambiguous, and where the consequences of getting it wrong are hardest to undo.

Exogenous testosterone suppresses spermatogenesis in essentially everyone who takes it. The degree varies, the timeline varies, and recovery after stopping is common but neither guaranteed nor quick — it is frequently measured in months, sometimes longer, and a minority of men do not return to baseline. Duration of use and age both matter.

The practical implications:

• If you want children in the next few years, enclomiphene is the option that does not work against that, assuming your hypogonadism is secondary.
• If you are already on TRT and want children, stopping is not automatically sufficient, and there are recovery protocols that use SERMs and hCG. That is a specific clinical situation and worth addressing properly rather than waiting to see what happens.
• If you are done having children, this row of the table stops being decisive, and the comparison comes down to what levels you need and how you want to take it.
• If you are not sure, a baseline semen analysis before starting anything is cheap, fast, and the only way to know what you started with. Very few men get one, and it is the single most useful test in this decision.

Who Enclomiphene Suits, and Who It Does Not

Enclomiphene is not a gentler version of TRT. It is a different treatment with a narrower indication.

It tends to work well for younger men with secondary hypogonadism and an intact axis, men who want to preserve fertility, men who prefer a daily tablet to injections, and men whose low testosterone is associated with excess body weight — the phase III program specifically studied overweight men with secondary hypogonadism (5).

It tends not to work for men with primary hypogonadism, where the testes themselves have failed and a louder LH signal has nothing to act on. This is the most common reason enclomiphene disappoints, and it is knowable in advance from baseline LH and FSH: high LH and FSH with low testosterone points to a testicular problem, and enclomiphene is the wrong tool. Our article on the signs of low testosterone in men covers what that workup involves.

It also tends not to suit men who need consistently high-normal levels, men with certain retinal or visual conditions, and men whose axis has been suppressed by prolonged TRT use without a recovery period first.

One diagnostic caution: a pituitary cause such as a prolactinoma should be excluded rather than prescribed around. Secondary hypogonadism has causes that need identifying, and prolactin belongs in the baseline panel.

The Weight Connection Nobody Mentions

The most common cause of secondary hypogonadism in the men who ask this question is not a pituitary lesion. It is body fat, and it changes how the choice should be made.

Adipose tissue contains aromatase, the enzyme that converts testosterone to estradiol. More fat mass means more conversion, which means more estrogen feeding back on the hypothalamus and pituitary, which means less LH and FSH and less testosterone produced. The result is a self-reinforcing loop: low testosterone makes it harder to build muscle and easier to gain fat, and the added fat further suppresses testosterone. Our article on low testosterone and weight gain covers that cycle in more detail.

Two things follow, and both are relevant to the enclomiphene decision.

First, this is precisely the population the phase III program studied — overweight men with secondary hypogonadism (5) — so the evidence for enclomiphene is strongest in the men most likely to be asking. Blocking the feedback signal is a direct answer to feedback suppression caused by aromatization.

Second, and more importantly, meaningful weight loss raises testosterone on its own. A man who loses a substantial amount of fat frequently sees his own testosterone rise without any hormone treatment, because the aromatase load falls and the loop unwinds in the other direction. That is worth knowing before committing to a medication indefinitely, and it is a reason to run medical weight loss alongside the hormone conversation rather than after it.

Neither point argues against treatment. Both argue for treating the cause at the same time as the number.

What Results Look Like, and When

Weeks 1–2. Testosterone begins rising. LH and FSH move first.

Weeks 4–6. The first meaningful lab checkpoint: total and free testosterone, LH, FSH, and estradiol. This is where you learn whether the axis responded. If it has not moved, the answer is usually a revisited diagnosis rather than a higher dose.

Weeks 4–8. Energy and libido are the changes most commonly reported first, on roughly the same schedule as TRT.

Months 3–6. Body composition, mood, and training response, alongside resistance training and adequate protein rather than instead of them. A body-composition scan is more useful here than the scale. Our article on TRT before and after describes what is realistic across either route, because the downstream effects of normalized testosterone are broadly similar once levels are normalized.

Ongoing. Testosterone, estradiol, hematocrit, and — if fertility is the reason you chose this — a semen analysis to confirm the thing you selected it for is actually holding.

The fair expectation: enclomiphene generally delivers a normal testosterone level rather than a maximized one. Men who arrive expecting the levels quoted on forums by people running high-dose injectable protocols will be disappointed by the number even when they feel well.

Side Effects and Monitoring

Enclomiphene’s side-effect profile differs from TRT’s in ways that follow directly from the mechanism.

Because it raises testosterone and therefore estradiol, and because it is itself a SERM acting on estrogen receptors, the estrogen-related effects are the ones to watch: mood changes, breast tenderness, and, uncommonly, visual disturbance such as blurring or floaters. Visual symptoms are the ones worth acting on promptly rather than tolerating.

What it largely avoids: testicular atrophy, the fertility suppression discussed above, and the injection-site issues and peak-and-trough swings of an injectable protocol. Hematocrit still needs checking, though significant erythrocytosis is less common than on TRT.

What it shares with TRT: the need for a clinician reading periodic labs and adjusting. Our article on TRT side effects covers the comparison from the other direction, and SHBG explains why free testosterone frequently tells a different story from the total on either treatment.

Cost, Practicality, and the Compounding Question

A daily oral tablet suits some lives considerably better than a weekly injection, and for men who have avoided treatment entirely because of needles, that is not a trivial advantage.

Cost varies because the product is compounded rather than manufactured to a label, and it is generally not covered by insurance for this use. Injectable testosterone remains the least expensive route overall. Our breakdown of testosterone therapy cost covers how the routes compare.

The compounding point deserves a sentence of its own. Because there is no approved enclomiphene product, what you receive depends on the pharmacy’s sourcing and quality control. This is a reasonable thing to ask about directly: which pharmacy, whether it is licensed in your state, and whether it is a 503A or 503B facility.

Switching Between Them

TRT to enclomiphene. This is not a simple swap, because prolonged exogenous testosterone suppresses the axis and it does not restart the day you stop. Depending on how long you have been on treatment, a recovery protocol may be needed before enclomiphene has an axis to work with. Expect a period of feeling worse in between, and plan for it rather than discovering it.

Enclomiphene to TRT. Straightforward. If enclomiphene has not produced adequate levels or symptom relief after a fair trial, moving to TRT is a reasonable next step, and the fertility conversation should be revisited and documented before it happens.

Using both. Some protocols combine testosterone with hCG or a SERM to maintain testicular function. That is a more involved approach with its own monitoring requirements and is not a starting point.

How We Decide at Rewind

The decision is made on the baseline panel, not on preference, and the panel is the part most often skipped elsewhere.

Before anything is prescribed we want confirmed morning total and free testosterone on more than one occasion, LH and FSH — which is what separates secondary from primary hypogonadism and therefore determines whether enclomiphene is even a candidate — plus estradiol, SHBG, prolactin, thyroid function, hematocrit, and a PSA where age-appropriate. We ask about fertility intentions before the first prescription rather than after, and we recommend a baseline semen analysis for any man who is not certain he is finished having children.

From there: high LH and FSH with low testosterone means enclomiphene will not work and testosterone therapy is the conversation. Low or normal LH and FSH with low testosterone means both are on the table, and fertility, preferred route, and the levels you actually need decide it. Either way there is a recheck at four to six weeks that changes the plan if the numbers say so.

If you have been told TRT is your only option and nobody mentioned your LH and FSH, that is worth a second opinion before you start something that takes months to reverse.

This article is for general education and is not medical advice. Testosterone and enclomiphene therapy require laboratory confirmation, evaluation of your individual history, and ongoing monitoring. Discuss any treatment with a qualified clinician.

Sources

1. Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. PubMed. pubmed.ncbi.nlm.nih.gov/31063005/
2. Wiehle RD, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int. pubmed.ncbi.nlm.nih.gov/23875626/
3. Kaminetsky J, et al. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. onlinelibrary.wiley.com/doi/abs/10.1111/jsm.12116
4. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. fertstert.org/article/S0015-0282(14)00537-8/fulltext
5. Phase III study to evaluate morning testosterone normalization in men with secondary hypogonadism. ClinicalTrials.gov NCT01532414. clinicaltrials.gov/study/NCT01532414